PRVL.OQ
Latest Trade
22.93USDChange
0.02(+0.09%)Volume
128,149Today's Range
-
23.0352 Week Range
-
23.35As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 22.91 |
|---|---|
Open | 22.95 |
Volume | 128,149 |
3M AVG Volume | 9.02 |
Today's High | 23.03 |
Today's Low | 22.85 |
52 Week High | 23.35 |
52 Week Low | 9.03 |
Shares Out (MIL) | 34.25 |
Market Cap (MIL) | 785.31 |
Forward P/E | -9.55 |
Dividend (Yield %) | -- |
Prevail Therapeutics Must Pay Eli Lilly Termination Fee Of $30 Mln In Event That Deal Terminated By Eli Lilly
Prevail Therapeutics Announces First Patient Dosed In Phase 1/2 Proclaim Clinical Trial Evaluating PR006 For The Treatment Of Frontotemporal Dementia Patients With GRN Mutations
Prevail Therapeutics Expects To Initiate Enrollment In Phase 1/2 Proclaim Trial Of Pr006 In Q4 Of 2020
Prevail Therapeutics Inc. is a gene therapy company. The Company is developing and commercializing adeno-associated virus (AAV)-based gene therapies for patients with neurodegenerative diseases. It is engaged in applying a precision medicine approach to neurodegeneration by studying its gene therapies in genetically defined patient populations. The Company’s lead program is PR001 for the treatment of Parkinson’s disease with gaucher disease mutation, and neuronopathic gaucher disease. The Company is focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.
Industry
Biotechnology & Drugs
Contact Info
430 E 29th St Ste 940
NEW YORK, NY
10016-8367
United States
+1.917.3369310
https://www.prevailtherapeutics.com/Executive Leadership
Francois E. Nader
Independent Chairman of the Board
Asa Abeliovich
President, Chief Executive Officer, Director
Brett I. Kaplan
Chief Financial Officer
Yong Dai
Chief Technology Officer
Kira Schwartz
General Counsel
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 6.98 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -49.17 |
Return on Equity (TTM) | -45.68 |
* PREVAIL THERAPEUTICS REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
* PREVAIL THERAPEUTICS PROVIDES CLINICAL ADVANCEMENT UPDATE ON PR001 FOR THE TREATMENT OF PARKINSON’S DISEASE WITH GBA1 MUTATIONS
* PREVAIL THERAPEUTICS ANNOUNCES INVESTIGATIONAL NEW DRUG APPLICATION ACTIVE FOR PR006 FOR THE TREATMENT OF FRONTOTEMPORAL DEMENTIA WITH GRN MUTATION Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.